Replimune Group Stock Analysis

Replimune Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The book value of Replimune was at this time reported as 5.58. The company recorded a loss per share of 3.04. Replimune Group had not issued any dividends in recent years. Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 206 people. To find out more about Replimune Group contact Robert Coffin at 781 222 9600 or learn more at https://www.replimune.com.

Replimune Group Investment Alerts

Replimune Group Upcoming and Recent Events

Replimune Largest EPS Surprises

View All Earnings Estimates

Replimune Environmental, Social, and Governance (ESG) Scores

Replimune Stock Institutional Investors

Note, although Replimune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Replimune Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.02 B.

Replimune Profitablity

Management Efficiency

Replimune Group has return on total asset (ROA) of (0.2707) % which means that it has lost $0.2707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5032) %, meaning that it created substantial loss on money invested by shareholders. Replimune's management efficiency ratios could be used to measure how well Replimune manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.46. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Replimune's Net Tangible Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.10 this year, although the value of Total Assets will most likely fall to about 359.6 M.

Technical Drivers

As of the 26th of November, Replimune holds the Risk Adjusted Performance of 0.109, semi deviation of 2.86, and Coefficient Of Variation of 764.02. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Replimune, as well as the relationship between them. Please check Replimune Group variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Replimune Group is priced some-what accurately, providing market reflects its current price of 13.26 per share. Given that Replimune has jensen alpha of 0.4715, we recommend you to check out Replimune Group's recent market performance to make sure the company can sustain itself at a future point.

Replimune Group Price Movement Analysis

Replimune Group Insider Trading Activities

Replimune Outstanding Bonds

Replimune Predictive Daily Indicators

Replimune Corporate Filings

Replimune Forecast Models

Replimune's time-series forecasting models are one of many Replimune's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Replimune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Replimune prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Replimune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Replimune. By using and applying Replimune Stock analysis, traders can create a robust methodology for identifying Replimune entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Replimune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Replimune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Replimune Group stock analysis indicators help investors evaluate how Replimune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Replimune shares will generate the highest return on investment. By understating and applying Replimune stock analysis, traders can identify Replimune position entry and exit signals to maximize returns.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.